Clare Ozawa
InvestorManaging Director at Versant Ventures
San Diego, California
Writes $100K – $5M checks · typically $1.5M
About
Clare Ozawa combines a Stanford Ph.D. with experience as COO/CBO at Inception Sciences, leads San Diego–Bay Area investments and sits on boards of Capsida, Lycia, Gate Bioscience and 858 Therapeutics.
Invests in
BiotechHealthtechMedical Devices
Experience
- Versant VenturesManaging Directorcurrent2017 — present
- Inception SciencesChief Operating Officer, Chief Business Officer2011 — 2018
- Versant VenturesInvestment Professional2008 — 2010
- Versant EuroVenturesVP Business Development & Licensing2008 — 2010
- NovartisAssistant to CEO Pharma2006 — 2008
- McKinsey & CompanyEngagement Manager2002 — 2006
Education
- Stanford University School of MedicinePhD, Neurosciences
- Stanford UniversityB.S., Biological Sciences
Skills & more
+6 more
HealthcareLife SciencesStrategic PlanningStrategyManagementPharmaceutical IndustryFrom Clare's professional profile.
Same school
Also attended Stanford University School of Medicine67
+ 61 more
Also attended Stanford University1,575
+ 1,569 more
Shared employers
Also worked at Versant Ventures29
+ 23 more
Also worked at Novartis105
+ 99 more
Also worked at McKinsey & Company1,127
+ 1,121 more
Deals · 6
Lycia TherapeuticsBoard seat
via Versant Ventures · filed Jun 2026 · $75M raise
858 Therapeutics, Inc.Board seat
via Versant Ventures · filed Jul 2024 · $50.4M raise
Presbyopia TherapiesBoard seat
via Versant Ventures · filed Mar 2023 · $83.5M raise
March Therapeutics, Inc.Board seat
via Versant Ventures · filed Sep 2022 · $30.3M raise
Jengu Therapeutics, Inc.Board seat
via Versant Ventures · filed Sep 2020 · $50M raise
Mistral TherapeuticsBoard seat
via Versant Ventures · filed Jun 2018 · $59.3M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Versant Ventures
Network5
Investors connected to Clare in public investor directories — a warm-intro map.
























.jpg)





